/ISEE

ISEE Stock - IVERIC bio, Inc.

Q: What is the analyst price target for ISEE?

Analyst price target information is not currently available for ISEE.

Q: What is ISEE's market cap?

Market capitalization information is not currently available for ISEE.

Healthcare|Biotechnology|NASDAQ

$39.95+0.38%

+$0.15 (+0.38%) • Jul 10

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-18.0%upside

Target: $32.76

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ISEE

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.10

52W High$39.99

52W Low$9.39

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-189,906,000	$-114,757,000	$-88,736,000	$-61,272,000	$-65,349,000
Net Income	$-175,745,000	$-114,238,000	$-84,547,000	$-58,859,000	$63.09M
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-1.45	$-1.12	$-1.14	$-1.39	$1.70

Company Overview

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

38%

Hold / Neutral

50%

Sell / Underperform

13%

Analyst Consensus🔴 Bearish

3 Bullish5 Neutral/Bearish

Price Targets

$18

Average Target

↓ 54.9% Downside

Now

Low

$18

Average

$30

High

Based on 6 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
May 1st 2023	Guggenheim	Downgrade	Neutral	-
November 10th 2022	Jefferies	Downgrade	Hold	$20← $30
October 17th 2022	B. Riley Securities	Upgrade	Neutral	-
September 6th 2022	B. Riley Securities	Downgrade	Sell	$8← $12
August 2nd 2022	UBS	Initiation	Buy	$20
June 8th 2022	Guggenheim	Initiation	Buy	$30
June 8th 2022	BofA Securities	Initiation	Buy	$18
May 12th 2022	B. Riley Securities	Initiation	Neutral	$12

Earnings History & Surprises

ISEE

Beat Rate

27%

Last 15 quarters

Avg Surprise

-9.1%

EPS vs Estimate

Beats / Misses

4/10

1 met exactly

Latest EPS

$-0.41

Q3 2023

EPS Surprise History

Q4 21

+20.7%

$-0.23vs$-0.29

Q1 22

-20.8%

$-0.29vs$-0.24

Q2 22

0.0%

$-0.29vs$-0.29

Q3 22

-32.3%

$-0.41vs$-0.31

Q4 22

+12.5%

$-0.35vs$-0.40

Q1 23

-27.0%

$-0.47vs$-0.37

Q2 23

-20.5%

$-0.53vs$-0.44

Q3 23

+16.3%

$-0.41vs$-0.49

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	May 8, 2024	—	—	—	—
Q1 2024	Feb 28, 2024	—	—	—	—
Q4 2023	Nov 1, 2023	—	—	—	—
Q3 2023	Jul 25, 2023	$-0.49	$-0.41	+16.3%	✓ BEAT
Q2 2023	May 10, 2023	$-0.44	$-0.53	-20.5%	✗ MISS
Q1 2023	Mar 1, 2023	$-0.37	$-0.47	-27.0%	✗ MISS
Q4 2022	Nov 3, 2022	$-0.40	$-0.35	+12.5%	✓ BEAT
Q3 2022	Jul 26, 2022	$-0.31	$-0.41	-32.3%	✗ MISS
Q2 2022	May 4, 2022	$-0.29	$-0.29	0.0%	= MET
Q1 2022	Feb 24, 2022	$-0.24	$-0.29	-20.8%	✗ MISS
Q4 2021	Nov 9, 2021	$-0.29	$-0.23	+20.7%	✓ BEAT
Q3 2021	Aug 4, 2021	$-0.26	$-0.32	-23.1%	✗ MISS
Q2 2021	May 5, 2021	$-0.27	$-0.29	-7.4%	✗ MISS
Q1 2021	Mar 3, 2021	$-0.24	$-0.27	-12.5%	✗ MISS
Q4 2020	Nov 2, 2020	$-0.21	$-0.27	-28.6%	✗ MISS
Q3 2020	Aug 5, 2020	$-0.31	$-0.32	-3.2%	✗ MISS
Q2 2020	May 6, 2020	$-0.39	$-0.28	+28.2%	✓ BEAT
Q1 2020	Feb 27, 2020	$-0.28	$-0.39	-39.3%	✗ MISS
Q4 2019	Nov 12, 2019	—	$-0.35	—	—
Q3 2019	Aug 1, 2019	—	$-0.35	—	—